Do analysts prefer DBVT or BNR?

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 394.90%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe DBV Technologies is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer DBVT or BNR?

In the previous week, DBV Technologies had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat DBV Technologies' score of -0.91 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative Burning Rock Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend WVE or BNR?

WAVE Life Sciences currently has a consensus target price of $21.65, suggesting a potential upside of 525.64%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe WAVE Life Sciences is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score WAVE Life Sciences 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.78 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to WVE or BNR?

In the previous week, WAVE Life Sciences had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 4 mentions for WAVE Life Sciences and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat WAVE Life Sciences' score of -0.15 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Burning Rock Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer FTH or BNR?

Sensei Biotherapeutics presently has a consensus price target of $56.25, suggesting a potential upside of 116.10%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.93 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor FTH or BNR?

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat Sensei Biotherapeutics' score of 0.11 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Burning Rock Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BNR or VSTM?

Verastem has a consensus target price of $13.83, suggesting a potential upside of 65.08%. Given Verastem's stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verastem 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75

Does the media refer more to BNR or VSTM?

In the previous week, Verastem had 12 more articles in the media than Burning Rock Biotech. MarketBeat recorded 14 mentions for Verastem and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat Verastem's score of 0.24 indicating that Burning Rock Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MDXG or BNR?

MiMedx Group currently has a consensus price target of $8.57, suggesting a potential upside of 83.54%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiMedx Group 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer MDXG or BNR?

In the previous week, MiMedx Group had 4 more articles in the media than Burning Rock Biotech. MarketBeat recorded 6 mentions for MiMedx Group and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat MiMedx Group's score of 0.20 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Burning Rock Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Burning Rock Biotech (BNR) Competitors

$15.49 +0.29 (+1.91%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.59 +0.10 (+0.65%)

As of 10/9/2026 06:21 PM Eastern

Compare

BNR vs. DBVT, WVE, FTH, VSTM, and MDXG

Should you buy Burning Rock Biotech stock or one of its competitors? Burning Rock Biotech's main competitors and comparable companies include DBV Technologies (DBVT), WAVE Life Sciences (WVE), Sensei Biotherapeutics (FTH), Verastem (VSTM), and MiMedx Group (MDXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Burning Rock Biotech compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Burning Rock Biotech has a net margin of -13.60% compared to DBV Technologies' net margin of -3,506.53%. Burning Rock Biotech's return on equity of -12.98% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

Burning Rock Biotech has higher revenue and earnings than DBV Technologies. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	109.26	-$146.95M	-$3.51	N/A
Burning Rock Biotech	$77.16M	2.11	-$7.92M	-$0.87	N/A

DBV Technologies has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

In the previous week, DBV Technologies had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat DBV Technologies' score of -0.91 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
Burning Rock Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 394.90%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe DBV Technologies is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Burning Rock Biotech beats DBV Technologies on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

WAVE Life Sciences currently has a consensus target price of $21.65, suggesting a potential upside of 525.64%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe WAVE Life Sciences is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has a net margin of -13.60% compared to WAVE Life Sciences' net margin of -309.73%. Burning Rock Biotech's return on equity of -12.98% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, WAVE Life Sciences had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 4 mentions for WAVE Life Sciences and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat WAVE Life Sciences' score of -0.15 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Burning Rock Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Burning Rock Biotech has higher revenue and earnings than WAVE Life Sciences. Burning Rock Biotech is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	15.96	-$204.38M	-$1.09	N/A
Burning Rock Biotech	$77.16M	2.11	-$7.92M	-$0.87	N/A

WAVE Life Sciences has a beta of -1.43, suggesting that its share price is 243% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Summary

Burning Rock Biotech beats WAVE Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat Sensei Biotherapeutics' score of 0.11 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Burning Rock Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Burning Rock Biotech has higher revenue and earnings than Sensei Biotherapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Burning Rock Biotech	$77.16M	2.11	-$7.92M	-$0.87	N/A

Sensei Biotherapeutics presently has a consensus price target of $56.25, suggesting a potential upside of 116.10%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sensei Biotherapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

Sensei Biotherapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Summary

Burning Rock Biotech beats Sensei Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Verastem?

Burning Rock Biotech (NASDAQ:BNR) and Verastem (NASDAQ:VSTM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 1.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Verastem had 12 more articles in the media than Burning Rock Biotech. MarketBeat recorded 14 mentions for Verastem and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat Verastem's score of 0.24 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Burning Rock Biotech has higher revenue and earnings than Verastem. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	2.11	-$7.92M	-$0.87	N/A
Verastem	$30.91M	24.55	-$209.47M	-$2.66	N/A

Verastem has a consensus target price of $13.83, suggesting a potential upside of 65.08%. Given Verastem's stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Burning Rock Biotech has a net margin of -13.60% compared to Verastem's net margin of -231.59%. Burning Rock Biotech's return on equity of -12.98% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
Verastem	-231.59%	-467.49%	-94.54%

Burning Rock Biotech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Verastem has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Summary

Burning Rock Biotech beats Verastem on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

MiMedx Group has a net margin of 1.76% compared to Burning Rock Biotech's net margin of -13.60%. MiMedx Group's return on equity of 12.09% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

MiMedx Group currently has a consensus price target of $8.57, suggesting a potential upside of 83.54%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, MiMedx Group had 4 more articles in the media than Burning Rock Biotech. MarketBeat recorded 6 mentions for MiMedx Group and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.75 beat MiMedx Group's score of 0.20 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Burning Rock Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.63	$48.58M	$0.04	116.75
Burning Rock Biotech	$77.16M	2.11	-$7.92M	-$0.87	N/A

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats Burning Rock Biotech on 12 of the 16 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$159.88M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-17.80	13.42	274.15	26.16
Price / Sales	2.11	1,237.85	590.48	94.54
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.13	17.17	11.21	6.34
Net Income	-$7.92M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-4.68%	-1.33%	-0.90%	-1.41%
1 Month Performance	33.30%	-8.44%	-4.44%	-3.48%
1 Year Performance	85.29%	14.02%	6.96%	1.16%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	0.6975 of 5 stars	$15.49 +1.9%	N/A	+80.5%	$159.88M	$77.16M	N/A	667	Gap Down
DBVT DBV Technologies	3.4059 of 5 stars	$11.55 -0.8%	$48.50 +319.9%	-38.2%	$731.90M	$5.64M	N/A	161
WVE WAVE Life Sciences	2.6081 of 5 stars	$3.64 -0.8%	$22.31 +513.0%	-57.8%	$723.17M	$42.73M	N/A	317
FTH Sensei Biotherapeutics	3.0654 of 5 stars	$28.07 +1.1%	$56.25 +100.4%	N/A	$717.59M	N/A	N/A	29	Short Interest Increase
VSTM Verastem	3.6037 of 5 stars	$7.92 +1.9%	$13.83 +74.7%	-9.3%	$703.68M	$30.91M	N/A	102	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. DBVT, WVE, FTH, VSTM, and MDXG

How does Burning Rock Biotech compare to DBV Technologies?

Summary

How does Burning Rock Biotech compare to WAVE Life Sciences?

Summary

How does Burning Rock Biotech compare to Sensei Biotherapeutics?

Summary

How does Burning Rock Biotech compare to Verastem?

Summary

How does Burning Rock Biotech compare to MiMedx Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. DBVT, WVE, FTH, VSTM, and MDXG

How does Burning Rock Biotech compare to DBV Technologies?

Is DBVT or BNR more profitable?

Which has higher valuation and earnings, DBVT or BNR?

Which has more risk & volatility, DBVT or BNR?

Does the media prefer DBVT or BNR?

Do institutionals and insiders have more ownership in DBVT or BNR?

Do analysts prefer DBVT or BNR?

Summary

How does Burning Rock Biotech compare to WAVE Life Sciences?

Do analysts recommend WVE or BNR?

Is WVE or BNR more profitable?

Do insiders & institutionals hold more shares of WVE or BNR?

Does the media refer more to WVE or BNR?

Which has better valuation and earnings, WVE or BNR?

Which has more risk & volatility, WVE or BNR?

Summary

How does Burning Rock Biotech compare to Sensei Biotherapeutics?

Do insiders and institutionals have more ownership in FTH or BNR?

Does the media favor FTH or BNR?

Which has better earnings and valuation, FTH or BNR?

Do analysts prefer FTH or BNR?

Is FTH or BNR more profitable?

Which has more risk & volatility, FTH or BNR?

Summary

How does Burning Rock Biotech compare to Verastem?

Do institutionals & insiders hold more shares of BNR or VSTM?

Does the media refer more to BNR or VSTM?

Which has preferable valuation & earnings, BNR or VSTM?

Do analysts recommend BNR or VSTM?

Is BNR or VSTM more profitable?

Which has more volatility and risk, BNR or VSTM?

Summary

How does Burning Rock Biotech compare to MiMedx Group?

Is MDXG or BNR more profitable?

Do analysts rate MDXG or BNR?

Does the media prefer MDXG or BNR?

Which has more risk and volatility, MDXG or BNR?

Which has stronger earnings and valuation, MDXG or BNR?

Do institutionals and insiders have more ownership in MDXG or BNR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools